Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
Open Access
- 12 August 2021
- journal article
- research article
- Published by BMJ in BMJ Neurology Open
- Vol. 3 (2), e000164
- https://doi.org/10.1136/bmjno-2021-000164
Abstract
Objective Spinal muscular atrophy (SMA) is a motor neuron disease caused by low levels of survival motor neuron (SMN) protein. Prior work in models and patients has demonstrated electrophysiological and morphological defects at the neuromuscular junction (NMJ). Therapeutic development has resulted in clinically available therapies to increase SMN protein levels in patients and improve muscle function. Here we aimed to investigate the effect of SMN restoration (via nusinersen) on NMJ transmission in adults with SMA. Methods Participants undergoing nusinersen treatment underwent 3 Hz repetitive nerve stimulation (RNS) of the spinal accessory nerve to assess compound muscle action potential amplitude decrement. Maximum voluntary isometric contraction (MVICT), Revised Upper Limb Module (RULM), and 6 min walk test (6MWT) were assessed for correlations with decrement. Results Data from 13 ambulatory (7 men/6 women, mean age 40±11 years) and 11 non-ambulatory (3 men/8 women, mean age 38±12 years) participants were analysed. Cross-sectional analyses of RNS decrement were similar at 14 months of nusinersen (−14.2%±11.5%, n=17) vs baseline (−11.9%±8.3%, n=15) (unpaired t-test, p=0.5202). Longitudinal comparison of decrement in eight participants showed no change at 14 months (−13.9%±6.7%) vs baseline (−16.9%±13.4%) (paired t-test, p=0.5863). Decrement showed strong correlations with measures of MVICT, RULM and 6MWT but not age or disease duration. Conclusion Adults with SMA had significant NMJ transmission defects that were not corrected with 14 months of nusinersen treatment. NMJ defects were negatively associated with physical function, and thus may represent a promising target for additive or combinatorial treatments.Keywords
Funding Information
- Cure SMA (ELS1819)
This publication has 42 references indexed in Scilit:
- Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3Neurology, 2012
- Evaluation of Neuromuscular Junction Disorders in the Electromyography LaboratoryNeurologic Clinics, 2012
- Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophyNeurology, 2010
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- An analysis of disease severity based on SMN2 copy number in adults with spinal muscular atrophyMuscle & Nerve, 2009
- Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?Nature Reviews Neuroscience, 2009
- Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy MiceJournal of Neuroscience, 2009
- A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophyNeuromuscular Disorders, 2006
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005
- The Neurobiology of Childhood Spinal Muscular AtrophyNeurobiology of Disease, 1996